Sanofi — Regulatory Filings 2020

Feb 6, 2020

6-K 1 d860609d6k.htm 6-K 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2020

Commission File Number: 001-31368

SANOFI

(Translation of registrant’s name into English)

54, rue La Boétie, 75008 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

In February 2020, Sanofi issued the press releases and the statement attached hereto as Exhibit 99.1, 99.2 and 99.3 which are incorporated herein by reference.

Exhibit List

Exhibit No.	Description
Exhibit 99.1	Press release dated February 6, 2020: Sanofi delivers strong 2019 business EPS growth of 6.8% at CER
Exhibit 99.2	Press release dated February 6, 2020: Sanofi brain-penetrant BTK inhibitor meets primary endpoint of Phase 2 trial in relapsing multiple sclerosis
Exhibit 99.3	Product Sales Statement, for the Product Sales Measuring Period Ended December 31, 2019

2

Exhibit Index

Exhibit No.	Description
Exhibit 99.1	Press release dated February 6, 2020: Sanofi delivers strong 2019 business EPS growth of 6.8% at CER
Exhibit 99.2	Press release dated February 6, 2020: Sanofi brain-penetrant BTK inhibitor meets primary endpoint of Phase 2 trial in relapsing multiple sclerosis
Exhibit 99.3	Product Sales Statement, for the Product Sales Measuring Period Ended December 31, 2019

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: February 6, 2020	SANOFI
By	/s/ Alexandra Roger
Name:	Alexandra Roger
Title:	Head of Securities Law and Capital
Markets

4